CDXC FY2025 SEC EDGAR DEF 14A #61 of 168 in industry

Niagen Bioscience, Inc. CEO pay ratio

The CEO earned $8.4M in FY2025 against median worker pay of $124,378 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-29
Industry
Chemicals & Pharmaceuticals
Industry rank
#61/168

Data updated August 2026

Subscribe to Niagen Bioscience, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
67:1
Moderate (Scale: 0–1000:1)
CEO pay
$8.4M
Median worker
$124,378

Answer first

Niagen Bioscience, Inc.'s FY2025 CEO total of $8.4M ranks #652 of 1,423 complete filings; its 67:1 pay ratio ranks #847. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $124,378. Industry placement uses the FY2025 SIC-28 peer cohort (# 61 of 168, 64th percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#652
$8.4M of 1,423 FY2025
Ratio rank
#847
67:1 of 1,423
Industry pct
64th
above the industry median pay ratio

How Niagen Bioscience, Inc. ranks nationally

Niagen Bioscience, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$8,381,900 Top 46% higher than 54% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Niagen Bioscience, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($8.4M) against pay ratio (67:1) for Niagen Bioscience, Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both7015949.311875670.916735392.521595114.126454835.840.5:148.5:156.5:164.5:172.5:1CEO total payPay ratio (CEO : median worker)Niagen Bioscience, Inc., CEO total pay: 8381900 · Pay ratio (CEO : median worker): 67:1Niagen Bioscience, Inc.Tg Therapeutics, Inc., CEO total pay: 25571250 · Pay ratio (CEO : median worker): 67:1Tg Therapeutics, Inc.Jazz Pharmaceuticals plc, CEO total pay: 19418256 · Pay ratio (CEO : median worker): 69:1Jazz Pharmaceuticals plcEcovyst Inc., CEO total pay: 10023845 · Pay ratio (CEO : median worker): 65:1Ecovyst Inc.Chemours Co, CEO total pay: 8600301 · Pay ratio (CEO : median worker): 71:1Chemours Co
Niagen Bioscience, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Niagen Bioscience, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Niagen Bioscience, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
67:1
FY2025
vs prior FY
+58:1
from FY2024 9:1
CEO $ YoY
+592%
$8.4M latest
Filings shown
4
FY2022–2025
Niagen Bioscience, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $1.2M - $120,000 10:1 -
2023 $1.2M +0.1% $129,600 9:1 -1:1
2024 $1.2M +4.5% $130,524 9:1 0:1
2025 $8.4M +592% $124,378 67:1 +58:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1386570, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
67:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$8.4M
Companies in Industry
168
vs. Industry Median
Above
#61 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Niagen Bioscience, Inc.: MODEST · HEAVY pay ratio

Niagen Bioscience, Inc. disclosed 67:1 CEO-to-worker pay and $8.4M CEO total in FY2025. the CEO earned 67× the median employee ($124,378) in FY2025.

Median employee $124,378 (ELITE-MED); MODEST · HEAVY stamps put about 67 median-wage years per CEO year.

CEO Total Pay

$8.4M

FY2025 Summary Compensation, near median

Pay Ratio

67:1

Near industry median

What FY2025 shows for Niagen Bioscience, Inc.

Niagen Bioscience, Inc. disclosed 67:1 CEO-to-worker pay and $8.4M CEO total in FY2025. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Niagen Bioscience, Inc.'s $8.4M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #652 and ratio rank #847 split - treat 67:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$8.4M
Median Employee Pay
$124,378
Pay Ratio
67:1
Filing Date
2026-04-29

Company Info

Ticker
CDXC
CIK
1386570
Industry
Chemicals & Pharmaceuticals
SIC Code
2833
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1386570, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Niagen Bioscience, Inc. disclosed 67:1 CEO-to-worker pay and $8.4M CEO total in FY2025.

Read with Niagen Bioscience, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Lincoln Electric Holdings Inc · HEAVY

ABS(ceo_total_comp) peer at $8.4M (Δ $13K heavier vs Niagen Bioscience, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Clarivate PLC · HEAVY

ABS(ceo_total_comp) peer at $8.4M (Δ $31K lighter vs Niagen Bioscience, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
KEMPER Corp · HEAVY

ABS(ceo_total_comp) peer at $8.4M (Δ $32K heavier vs Niagen Bioscience, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Sterling Infrastructure, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.4M (Δ $34K heavier vs Niagen Bioscience, Inc.); MID · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Tg Therapeutics, Inc. (SIC 28 pole)

Tg Therapeutics, Inc. stamps MODEST · PEAK nearest in-SIC by ABS(pay_ratio) to Niagen Bioscience, Inc.'s MODEST filing.
National dual ranks · #652/#847

Niagen Bioscience, Inc.'s FY2025 package sits #652 by CEO dollars and #847 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Niagen Bioscience, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Niagen Bioscience, Inc. (CIK 1386570), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.